Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of Oncology

• Publication date

  2013-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mds290PMID 23038762
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.

  2013cited by this paper
• Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.

  2012cited by this paper
• Phase II trial of galiximab ( anti-CD 80 monoclonal antibody ) plus rituximab ( CALGB 50402 ) : Follicular Lymphoma International Prognostic Index ( FLIPI ) score is predictive of upfront immunotherapy responsiveness

  2012cited by this paper
• The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia

  2011cited by this paper
• P1-06-02: Correlation between Gene Variants in CYP19 (Aromatase) and TCL1A with Disease and Tolerability Endpoints in the ATAC Trial.

  2011cited by this paper
• Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.

  2011cited by this paper
• Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer

  2011cited by this paper
• Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.

  2011influential reference
• A prospective study of aromatase inhibitor‐associated musculoskeletal symptoms and abnormalities on serial high‐resolution wrist ultrasonography

  2010cited by this paper
• Menopausal arthralgia: Fact or fiction.

  2010cited by this paper
• Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.

  2010cited by this paper
• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

  2010cited by this paper
• Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.

  2010cited by this paper
• Update of the BIG 1-98 Trial: where do we stand?

  2009cited by this paper
• Patterns and risk factors associated with aromatase inhibitor‐related arthralgia among breast cancer survivors

  2009cited by this paper
• Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia.

  2009influential reference
• Selective estrogen receptor-β agonists repress transcription of proinflammatory genes

  2008cited by this paper
• Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.

  2008cited by this paper
• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

  2008cited by this paper
• Selective Estrogen Receptor-β Agonists Repress Transcription of Proinflammatory Genes1

  2008cited by this paper
• Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.

  2008influential reference
• Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.

  2008cited by this paper
• Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors

  2008cited by this paper
• Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

  2007cited by this paper
• Clinical features of joint symptoms observed in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial.

  2006cited by this paper
• Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.

  2006cited by this paper
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  2004cited by this paper
• A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

  2004cited by this paper
• Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

  2004cited by this paper
• The quality of physicians' health-care performance. A comparison against optimal criteria for treatment of the elderly and younger adults in community hospitals.

  1974cited by this paper
• Survivors

  1891cited by this paper

• Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review.

  2026cites this paper
• Inflammatory Rheumatic Disorders as a Complication of Endocrine Therapy for Breast Cancer

  2024cites this paper
• Rheumatic aspects of arthralgias associated with aromatase inhibitor therapy (analysis of a clinical case series)

  2023cites this paper
• Effect of whole-body cryotherapy versus placebo cryotherapy on joint pain induced by aromatase inhibitors in women with early stage breast cancer: a randomised clinical trial

  2023cites this paper
• The effectiveness of exercise on the symptoms in breast cancer patients undergoing adjuvant treatment: an umbrella review of systematic reviews and meta-analyses

  2023cites this paper
• Letrozole‐induced inflammatory arthritis and tendinopathy in pediatric rheumatology setting

  2023cites this paper
• Carpal tunnel syndrome and tenosynovitis in women with breast cancer associated with hormone therapy

  2022cites this paper
• Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.

  2022cites this paper
• Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management

  2021cites this paper
• Shear wave elastography detects novel imaging biomarkers of aromatase inhibitor–induced joint pain: a pilot study

  2021cites this paper
• The Effect of Combined Bone Marrow Aspirate, Lipoaspirate, and Platelet Rich Plasma Injections on Pain, Function, and Perceived Change Amongst Individuals with Severe Knee Osteoarthritis

  2021cites this paper
• Aromatase Inhibitor-Associated Musculoskeletal Symptoms #402

  2020cites this paper
• Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.

  2020cites this paper
• Hand tendinopathy risk factors in Taiwan

  2019cites this paper
• Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy

  2019cites this paper
• Comparing exercise responses to aerobic plus resistance training between postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy women

  2019cites this paper
• Case Report Oxygen-Ozone Therapy in Rheumatic Symptoms in 3 Patients with Breast Cancer Undergoing Aromatase-Inhibitors: A Successful Approach

  2019cites this paper
• The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis.

  2019cites this paper
• Osteoporosis and musculoskeletal complications related to therapy of breast cancer.

  2018cites this paper
• Adjuvant Endocrine Therapy

  2018cites this paper
• Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.

  2017cites this paper
• Grip Strength in Women Being Treated for Breast Cancer and Receiving Adjuvant Endocrine Therapy: Systematic Review

  2017cites this paper
• Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study)

  2017cites this paper
• Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.

  2016cites this paper
• Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS)

  2016cites this paper
• Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice

  2016cites this paper
• Drug-Induced Tendon Disorders.

  2016cites this paper
• Acupuncture for Treating Aromatase Inhibitor–Related Arthralgia in Breast Cancer: A Systematic Review and Meta-Analysis

  2015cites this paper
• Safety of aromatase inhibitor therapy in breast cancer

  2015cites this paper
• High-dosage tamoxifen as neoadjuvant treatment in minimally invasive surgery for Dupuytren disease in patients with a strong predisposition toward fibrosis: a randomized controlled trial.

  2014cites this paper
• COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy.

  2014cites this paper
• Aromatase inhibitors produce hypersensitivity in experimental models of pain : studies in vivo and in isolated sensory neurons

  2014cites this paper
• Aromatase inhibitors in the breast cancer clinic: focus on exemestane.

  2014cites this paper
• E12. Managing toxicity of aromatase inhibitors in early breast cancer

  2012cites this paper
• Managing the side effects of oral aromatase inhibitors

  2012cites this paper